Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Spina, M.
Right arrow Articles by Tirelli, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spina, M.
Right arrow Articles by Tirelli, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:655-656, 2003
© 2003 European Society for Medical Oncology

Letters to the Editor

High international prognostic score predicts a worse outcome for patients with Hodgkin’s disease and HIV infection: results of a prospective study with Stanford V regimen

M. Spina1, A. Re2, E. Vaccher1, J. Gabarre3 and U. Tirelli1

1 Division of Medical Oncology A, National Cancer Institute, Aviano; 2 Department of Internal Medicine, Civil Hospital, Brescia, Italy; 3 Department of Hematology, Hospital Pitie-Salpetriere, Paris, France

*E-mail: oma@cro.it

The first 10% of the full text of this article appears below.

Recently, Horning et al. reported the results of the Stanford V regimen in patients with locally extensive and advanced Hodgkin’s disease (HD) with a 5-year freedom from progression (FFP) of 89% and overall survival (OS) of 96% [1]. The authors stated that the FFP was significantly superior among patients with an international prognostic score (IPS) of 0–2 compared with those with an IPS >=3.

Hodgkin’s . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?